PFE.BA is trading 2.1% down at $9415.00 today, following news that a key lung cancer drug candidate acquired through Pfizer's $43 billion Seagen acquisition failed to meet its primary endpoints in a Phase 3 clinical trial. - The disappointing late-stage data for sigvotatug vedotin, announced June 23, 2026, marks a significant setback for Pfizer's oncology expansion roadmap. - This development weighs on investor sentiment, contrasting with the prior focus on Pfizer's AI integration and the broader Seagen deal execution.